14158 Results (Page 107 of 567)
All Market Research Reports
Kenya Asthma and COPD Therapeutics Market Analysis
The Kenya Asthma and COPD Therapeutics Market was valued at US $23 Mn in 2022, and is predicted to grow at (CAGR) of 6.30% from 2023 to 2030, to US $38 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and Asthma, supportive healthcare policies, increased awareness, and others. The industry is primarily dominated by players such as Abbott, Roche, AstraZeneca, Pfizer, Novartis, Cipla, and Boehringer-Ingelheim, among others.
Japan Asthma and COPD Therapeutics Market Analysis
The Japan Asthma and COPD Therapeutics Market was valued at US $2.076 Bn in 2022, and is predicted to grow at (CAGR) of 5.70% from 2023 to 2030, to US $3.235 Bn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and Asthma, supportive government initiatives, advancements in technology, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Daiichi Sankyo, Chugai, Sumitomo, and Mochida, among others.
Indonesia Asthma and COPD Therapeutics Market Analysis
The Indonesia Asthma and COPD Therapeutics Market was valued at US $200 Mn in 2022, and is predicted to grow at (CAGR) of 5.20% from 2023 to 2030, to US $301 Mn by 2030. The key drivers of this industry include the increasing prevalence of COPD and Asthma, rising economic growth, advancements in therapeutics, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Pfizer, GSK, Novartis, Abbott, and Boehringer Ingelheim, among others.
Vietnam Anemia Therapeutics Market Analysis
The Vietnam Anemia Therapeutics Market is anticipated to experience a growth from $74 Mn in 2022 to $151 Mn by 2030, with a CAGR of 9.3% during the forecast period of 2022-2030. High anemia prevalence, changing demographic trends and urbanization, and increased government support in the betterment of healthcare access among the population are among some factors that boost Vietnam market. The Vietnam Anemia Therapeutics Market encompasses various players across different segments, including Novartis, Pfizer, Roche, Bayer, Johnson & Johnson, Sanofi, AstraZeneca, Traphaco, Mekophar, Sao Kim Pharmaceutical etc, among various others
Germany HIV Drugs Market Analysis
Germany HIV Drugs Market is at around $1.16 Bn in 2023 and is projected to reach $1.31 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period. Increasing HIV prevalence, increased awareness and testing, and technological breakthroughs drive market growth. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Johnson & Johnson, and Bayer.
Singapore HIV Drugs Market Analysis
Singapore HIV Drugs Market is at around $38.04 Mn in 2023 and is projected to reach $50.74 Mn in 2030, exhibiting a CAGR of 4.2% during the forecast period. The market is being driven by developments in drug research, government initiatives, and the rising prevalence of HIV. The market is dominated by key players like Aslan Pharmaceuticals, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Indonesia HIV Drugs Market Analysis
Indonesia HIV Drugs Market is at around $0.19 Bn in 2023 and is projected to reach $0.24 Bn in 2030, exhibiting a CAGR of 3.6% during the forecast period. The market is growing as a result of government initiatives, rising HIV prevalence, and the expansion of healthcare infrastructure. The market is dominated by key players like PT Dexa Medica, PT Sanbe Farma, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd.
China HIV Drugs Market Analysis
China HIV Drugs Market is at around $2.55 Bn in 2023 and is projected to reach $3.61 Bn in 2030, exhibiting a CAGR of 5.1% during the forecast period. Increasing HIV/ AIDS prevalence, healthcare infrastructure improvement and new drug approvals and developments are all driving market expansion. The market is dominated by key players like Sinopharm, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceuticals, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, and AbbVie Inc.
UK HIV Drugs Market Analysis
UK HIV Drugs Market is at around $0.82 Bn in 2023 and is projected to reach $0.92 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period. Government initiatives, increased access to healthcare, and international partnerships are driving the sector. The market is dominated by key players like ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Johnson & Johnson, and Bayer.
South Africa HIV Drugs Market Analysis
South Africa HIV Drugs Market is at around $0.21 Bn in 2023 and is projected to reach $0.29 Bn in 2030, exhibiting a CAGR of 4.83% during the forecast period. The expansion of the market is due to factors such as collaboration and partnership with foreign organizations, the increasing prevalence of HIV/ Aids, and technological advancements in the field. The market is dominated by key players like Aspen Pharmacare, Adcock Ingram, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Kenya HIV Drugs Market Analysis
Kenya HIV Drugs Market is at around $22.19 Mn in 2023 and is projected to reach $30.6 Mn in 2030, exhibiting a CAGR of 4.7% during the forecast period. Government initiatives and policies, rising HIV prevalence, and expanding awareness and education are driving market expansion. The market is dominated by key players like Cosmos Limited, Universal Corporation, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Egypt HIV Drugs Market Analysis
Egypt HIV Drugs Market is at around $88.76 Mn in 2023 and is projected to reach $125.73 Mn in 2030, exhibiting a CAGR of 5.1% during the forecast period. The market is growing due to increased awareness, government initiatives, and international collaborations & funding. The market is dominated by key players like EVA Pharma, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Vietnam HIV Drugs Market Analysis
Vietnam HIV Drugs Market is at around $0.16 Bn in 2023 and is projected to reach $0.21 Bn in 2030, exhibiting a CAGR of 3.83% during the forecast period. Rising expenditure on healthcare, innovation in drug development, and international alliances and funding drive growth in the market. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., Novartis, and Mylan.
Philippines HIV Drugs Market Analysis
Philippines HIV Drugs Market is at around $69.74 Mn in 2023 and is projected to reach $92.39 Mn in 2030, exhibiting a CAGR of 4.1% during the forecast period. The market is growing as a result of government initiatives, the expansion of the healthcare infrastructure, and the rising prevalence of HIV/ AIDS. The market is dominated by key players like Unilab, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Malaysia HIV Drugs Market Analysis
Malaysia HIV Drugs Market is at around $50.72 Mn in 2023 and is projected to reach $65.85 Mn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The market is growing as a result of government initiatives, rising HIV prevalence, and the expansion of healthcare infrastructure. The market is dominated by key players like Pharmaniaga Berhad, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffmann-La Roche Ltd., and Novartis.
Japan HIV Drugs Market Analysis
Japan HIV Drugs Market is at around $1.97 Bn in 2023 and is projected to reach $2.61 Bn in 2030, exhibiting a CAGR of 4.1% during the forecast period. The market is growing as a result of government initiatives, rising HIV prevalence, and the expansion of healthcare infrastructure. The market is dominated by key players like Takeda Pharmaceutical Company, Eisai Co., Ltd., Daiichi Sankyo Company, Limited, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffmann-La Roche Ltd.
Spain HIV Drugs Market Analysis
Spain HIV Drugs Market is at around $0.61 Bn in 2023 and is projected to reach $0.73 Bn in 2030, exhibiting a CAGR of 2.6% during the forecast period. Increased HIV prevalence, improved access to healthcare, and advances in drug development are driving market expansion. The market is dominated by key players like Grifols, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Johnson & Johnson, and Bayer.
Mexico HIV Drugs Market Analysis
Mexico HIV Drugs Market is at around $0.48 Bn in 2023 and is projected to reach $0.62 Bn in 2030, exhibiting a CAGR of 3.85% during the forecast period. Increasing HIV prevalence, government initiatives, and the expansion of healthcare infrastructure are propelling the market growth. The market is dominated by key players like Genomma Lab Internacional, Laboratories Chinoin, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.
Brazil HIV Drugs Market Analysis
Brazil HIV Drugs Market is at around $0.79 Bn in 2023 and is projected to reach $1.09 Bn in 2030, exhibiting a CAGR of 4.6% during the forecast period. The market is expanding due to factors such as the high prevalence of HIV/ AIDS, government initiatives and healthcare policies, and rising spending on healthcare. The market is dominated by key players like Oswaldo Cruz Foundation (Fiocruz), Biolab Sanus, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.
UAE HIV Drugs Market Analysis
UAE HIV Drugs Market is at around $0.16 Bn in 2023 and is projected to reach $0.22 Bn in 2030, exhibiting a CAGR of 4.6% during the forecast period. Factors including improvements in drug development, rising healthcare costs, and migration and tourism are driving the market. The market is dominated by key players like Julphar, Neopharma, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.
Canada HIV Drugs Market Analysis
Canada HIV Drugs Market is at around $2.54 Bn in 2023 and is projected to reach $3.25 Bn in 2030, exhibiting a CAGR of 3.6% during the forecast period. The market is growing due to the prevalence of HIV/ AIDS, government initiatives and funding, and advancements in drug therapies. The market is dominated by key players like ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd., Cipla, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.
France HIV Drugs Market Analysis
France HIV Drugs Market is at around $0.87 Bn in 2023 and is projected to reach $1.04 Bn in 2030, exhibiting a CAGR of 2.6% during the forecast period. The market is being influenced by factors such as increased HIV incidence, government initiatives, and technological improvements. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Mylan, and Cipla.
US HIV Drugs Market Analysis
US HIV Drugs Market is at around $13.31 Bn in 2023 and is projected to reach $14.88 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period. The market is driven by rising HIV prevalence, improvements in drug development, and increased testing and awareness campaigns. The market is dominated by key players like Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd., Cipla, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.
South Africa Antifungal Drugs Market Analysis
South Africa Antifungal Drugs Market is at around $0.103 Bn in 2023 and is projected to reach $0.145 Bn in 2030, exhibiting a CAGR of 5.03% during the forecast period. The HIV/AIDS Epidemic, rising fungus infections, government initiatives, and healthcare spending are fueling the market's expansion. The market is dominated by key players like Aspen Pharmacare Holdings Limited, Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, Astellas Pharma Inc., Sanofi S.A., Bayer AG, Glenmark Pharmaceuticals Limited, and Gilead Sciences Inc.
Kenya Antifungal Drugs Market Analysis
Kenya Antifungal Drugs Market is at around $0.011 Bn in 2023 and is projected to reach $0.015 Bn in 2030, exhibiting a CAGR of 4.9% during the forecast period. The market is expanding due to the high prevalence of HIV/AIDS, technological advancements, and an aging population. The market is dominated by key players like Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, Astellas Pharma Inc., Sanofi S.A., Bayer AG, Glenmark Pharmaceuticals Limited, and Gilead Sciences Inc.
